Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice

被引:5
|
作者
Naranjo, Antonio [1 ]
Caceres, Laura [1 ]
Angel Hernandez-Beriain, Jose [2 ]
Francisco, Felix [1 ]
Ojeda, Soledad [1 ]
Talaverano, Sigrid [3 ]
Novoa-Medina, Javier [2 ]
Adan Martin, Jose [3 ]
Delgado, Esmeralda [4 ]
Trujillo, Elisa [4 ]
Alvarez, Fatima [5 ]
Magdalena, Laura [5 ]
Rodriguez-Lozano, Carlos [1 ]
机构
[1] Univ Las Palmas Gran Canaria, Hosp Univ Gran Canaria Dr Negrin, Dept Rheumatol, Las Palmas Gran Canaria 35010, Spain
[2] Complejo Hosp Univ Materno Insular Gran Canaria, Las Palmas Gran Canaria, Spain
[3] Hosp Dr Molina Orosa, Lanzarote, Spain
[4] Hosp Univ Canarias, Tenerife, Spain
[5] Hosp Univ NS Candelaria, Tenerife, Spain
关键词
Rheumatoid arthritis; Treat to target; DAS28; Ultrasonography; TO-TARGET STRATEGY; MUSCULOSKELETAL ULTRASOUND; RECOMMENDATIONS; RHEUMATOLOGISTS; OUTCOMES; IMPACT;
D O I
10.1007/s00296-015-3332-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the present study was to analyse the patterns of treatment adjustment in rheumatoid arthritis (RA) patients with active disease in routine clinical care. This was a cross-sectional study of consecutive patients with RA conducted in five hospitals. Activity scales (DAS28-ESR) and function (HAQ) were measured, as well as whether ultrasound was performed as part of the assessment. Treatment decision (no changes/reduction/intensification) and time to the next scheduled visit were the outcomes variables. Associated factors were analysed by multilevel regression models. A total of 343 patients were included (77 % women, mean age 57 years, mean RA duration 10 years), of whom 44 % were in remission by DAS28. Treatment was continued in 202 (59 %) patients, reduced in 57 (16 %), and intensified in 83 (24 %). In the 117 patients with active RA (DAS28 a parts per thousand yen 3.2), treatment was intensified in 61 (52 %). Factors associated with treatment intensification were physician and patient VAS, and DAS28, but not the centre. In the multilevel regression analysis with intensification of treatment as dependent variable, the following factors were significantly associated: DAS28 [OR 3.67 (95 % CI 2.43-5.52)], patient VAS [OR 1.04 (95 % CI 1.01-1.08)], and have performed an ultrasound [OR 3.36 (95 % CI 1.47-7.68)]. Factors associated with time to the next scheduled visit (an average of 4.3 months) were patient and physician VAS, DAS28, and centre. In clinical practice, half of the patients with active RA maintain or reduce the treatment. The decision to intensify treatment in active RA as recommended by a treat-to-target strategy is complex in practice.
引用
收藏
页码:1851 / 1855
页数:5
相关论文
共 50 条
  • [21] Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
    Leon, Leticia
    Rodriguez-Rodriguez, Luis
    Gomez-Gomez, Alejandro
    Macarron, Pilar
    Blanco, Margarita
    Jover, Juan A.
    Abasolo, Lydia
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [22] Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice
    Virkki, L. M.
    Konttinen, Y. T.
    Peltomaa, R.
    Suontama, K.
    Saario, R.
    Immonen, K.
    Jantti, J.
    Tuomiranta, T.
    Nykanen, P.
    Hameenkorpi, R.
    Heikkila, S.
    Isomaki, P.
    Nordstrom, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (06) : 1059 - 1066
  • [23] Treatment of rheumatoid arthritis (RA) with leflunomide (LEF) in routine clinical practice
    Irvine, S. A.
    McGhee, D.
    Fraser, S. M.
    Morrison, E.
    RHEUMATOLOGY, 2001, 40 : 33 - 33
  • [24] Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice
    Barbich, Tatiana
    Cerda, Osvaldo Luis
    Schneeberger, Emilce Edith
    Citera, Gustavo
    REUMATOLOGIA CLINICA, 2020, 18 (03): : 164 - 168
  • [25] Leflunomide for the treatment of rheumatoid arthritis in clinical practice - Incidence and severity of hepatotoxicity
    van Roon, EN
    Jansen, TLTA
    Houtman, NM
    Spoelstra, P
    Brouwers, JRBJ
    DRUG SAFETY, 2004, 27 (05) : 345 - 352
  • [26] Aminotransferase levels during treatment of rheumatoid arthritis with leflunomide in clinical practice
    Hoi, A
    Littlejohn, GO
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) : 379 - 379
  • [27] INTENSIVE TREATMENT OF EARLY RHEUMATOID ARTHRITIS: TRIALS VERSUS CLINICAL PRACTICE
    Ansel, Sonam
    Dale, James
    Porter, Duncan
    RHEUMATOLOGY, 2016, 55 : 103 - 103
  • [28] Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis
    Restrepo, Jose Felix
    del Rincon, Inmaculada
    Battafarano, Daniel F.
    Haas, Roy W.
    Doria, Merced
    Escalante, Agustin
    CLINICAL RHEUMATOLOGY, 2015, 34 (09) : 1529 - 1536
  • [29] Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis
    José Félix Restrepo
    Inmaculada del Rincón
    Daniel F. Battafarano
    Roy W. Haas
    Merced Doria
    Agustín Escalante
    Clinical Rheumatology, 2015, 34 : 1529 - 1536
  • [30] Hospitalization and associated factors in rheumatoid arthritis
    Loza, E.
    Abasolo, L.
    Clemente, D.
    Lopez-Gonzalez, R.
    Rodriguez, L.
    Vadillo, C.
    Fernandez-Gutierrez, B.
    Jover, J.
    Hernandez-Garcia, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 309 - 309